Related Experiment Video
Updated: Oct 1, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease
Mariana Caldas Waghabi1, Roberto Rodrigues Ferreira1,2, Rayane da Silva Abreu1
1Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Genômica Funcional e Bioinformática, Rio de Janeiro, RJ, Brasil.
Abstract:
Transforming growth factor beta (TGF-β) is deeply involved on the pathogenesis of Chagas disease. Our group has been investigating the participation of this pleiotropic cytokine in different aspects of Chagas disease over the last 20 years. Important observations have been made, such as: (i) the ability of Trypanosoma cruzi in activating latent TGF-β; (ii) the potential involvement of TGF-β pathway on T. cruzi invasion of host cells; (iii) association of TGF-β with parasite intracellular replication; (iv) cardiac fibrosis development and maintenance; (v) disruption of Connexin-43 plaque structures and (vi) inflammation and immune response. In this perspective article we intend to discuss the advances of the potential use of new therapies targeting TGF-β to treat the cardiac alterations of Chagas disease-affected patients.
Related Concept Videos
TGF - β Signaling Pathway
Heart Failure Drugs: Inotropic Agents
Myocarditis III: Medical Management
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Cardiomyopathy III: Hypertrophic Cardiomyopathy

